RGLS Share Price

Open 1.35 Change Price %
High 1.45 1 Day 0.03 2.22
Low 1.32 1 Week -0.07 -4.83
Close 1.38 1 Month -0.22 -13.75
Volume 2100553 1 Year -4.42 -76.21
52 Week High 6.25
52 Week Low 0.94
RGLS Important Levels
Resistance 2 1.50
Resistance 1 1.45
Pivot 1.38
Support 1 1.31
Support 2 1.26
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
DCTH 0.02 0.00%
SUSQ 14.20 -0.77%
ASTI 0.00 0.00%
SIRI 5.29 3.32%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
NIHD 0.74 39.62%
NIHD 0.74 39.62%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
AEZS 1.18 22.92%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Regulus Therapeutics Inc. (NASDAQ: RGLS)

RGLS Technical Analysis 4
As on 26th May 2017 RGLS Share Price closed @ 1.38 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.43 & Sell for SHORT-TERM with Stoploss of 1.49 we also expect STOCK to react on Following IMPORTANT LEVELS.
RGLS Target for May
1st Target up-side 1.74
2nd Target up-side 1.87
3rd Target up-side 2.01
1st Target down-side 1.36
2nd Target down-side 1.23
3rd Target down-side 1.09
RGLS Other Details
Segment EQ
Market Capital 170651968.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
RGLS Address
RGLS
N/A
RGLS Latest News
Interactive Technical Analysis Chart Regulus Therapeutics Inc. ( RGLS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regulus Therapeutics Inc.
RGLS Business Profile
Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases. microRNAs are naturally occurring ribonucleic acid (RNA), molecules that play a critical role in regulating key biological pathways. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs. As of December 31, 2012 , the Company�s operations included acquiring and in-licensing intellectual property rights, developing its microRNA, undertaking basic research around microRNA targets and conducting preclinical studies for its initial programs. The Company is developing RG-101 for the treatment of HCV and is advancing other microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis and metabolic diseases.